Opinion

Video

HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer

Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.

Background

  • Tucatinib is a highly selective HER2-directed TKI1 indicated for patients with previously treated HER2+ LA/MBC, including patients with brain metastases2-6
  • In HER2CLIMB, adding tucatinib to trastuzumab and capecitabine demonstrated HRs for PFS, OS, and PFS in patients with brain metastases of 0.54, 0.66, and 0.48 (P≤0.005 for all), respectively3
  • The incidence of brain metastases in patients with HER2+ LA/MBC remains high7-9; combining HER2-directed therapies can improve patient outcomes in HER2+ LA/MBC10,11
  • T-DM1 is a HER2-directed ADC approved for patients with HER2+ LA/MBC previously treated with trastuzumab and a taxane12
  • Preclinical data have shown that the combination of tucatinib and T-DM1 results in enhanced antitumor activity compared with either agent alone13
  • In a phase 1b/2 study, the combination of tucatinib and T-DM1 demonstrated encouraging antitumor activity, including intracranial responses, with a manageable safety profile14

Methods

  • HER2CLIMB-02 is a randomized, double-blind, placebo-controlled phase III study to evaluate efficacy and safety of TUC + T-DM1 in pts with unresectable locally advanced or metastatic HER2+ breast cancer; ∼460 pts randomized 1:1 to receive 21-day cycles of TUC (300 mg PO BID) or placebo with T-DM1 (3.6 mg/kg IV).
  • Pts must have had prior tx with Tras and a taxane in any setting, be ≥18 yrs, with an ECOG ≤1 and histologically confirmed HER2+ MBC. Prior tx with any investigational anti-HER2 or anti-EGFR agent or HER2 TKI is not permitted.

Conclusions

  • Adding tucatinib to T-DM1 significantly improved PFS in patients with previously treated HER2+ LA/MBC
    • Median PFS was 9.5 vs 7.4 months (HR, 0.76; P=0.0163)
    • PFS HRs for prespecified subgroups were consistent with that of the overall population
    • Median PFS for patients with brain metastases was 7.8 vs 5.7 months (HR, 0.64)
    • OS data are immature
  • Types of adverse events were consistent with those previously reported for tucatinib and T-DM1
    • Higher rate of hepatic events in the T-DM1 + Tucatinib arm; the events were generally transient, manageable, and reversible
  • This is the second randomized study which included patients with brain metastases to demonstrate that a tucatinib-containing regimen delays disease progression in HER2+ LA/MBC

Hurvitz S, Loi S, O’Shaughnessy J et al. HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer. Presented at: 2023 San Antonio Breast Cancer Symposium, December 5-9, 2023. San Antonio, Texas.

Related Videos
Sheldon M. Feldman, MD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
In this episode of OncChats: Empowering Community Cancer Care, Dr. Woodworth sheds light on the “Road to Recovery” survivorship program at Henry Mayo, which supports cancer survivors by providing them with fitness, education, and mental health resources, and underscores the importance of mentorship programs for community providers to ensure equitable cancer care.
In this episode of OncChats: Empowering Community Cancer Care, Drs Woodworth and Rai, discuss their collaborative approach to cancer screening, emphasizing the importance of community efforts and individual assessments in integrating genetic testing and screenings into routine practice.
In this episode of OncChats: Empowering Community Cancer Care, experts discuss the significance of community-based cancer care, emphasizing that most cancers are diagnosed locally and highlighting the importance of collaboration between primary care physicians and specialists to provide optimal education and treatment.
Sunil Adige, MD
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Key Data from the CYTO-PV and MAJIC-PV Studies: Evaluating Ruxolitinib in Polycythemia Vera
Lorenza Rimassa, MD